Mivacron (Mivacurium)

Mivacurium competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction. By preventing acetylcholine from binding, it stops depolarization of the motor end‑plate, resulting in a reversible loss of skeletal muscle tone and controlled paralysis.

The dose of Mivacron is individualized by the prescribing clinician based on patient weight, the required depth of muscle relaxation, and the surgical context. Typical dosing ranges are described in the product label, but exact amounts must be determined by a qualified healthcare professional.

Safety data for mivacurium in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and alternative agents should be considered when possible.

To order Mivacron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Mivacron is a short‑acting, non‑depolarizing agent, offering rapid onset and predictable recovery, unlike succinylcholine which is depolarizing and associated with hyperkalemia risk. Compared with longer‑acting agents such as rocuronium, mivacurium provides a shorter duration of action, making it useful for brief procedures or when quick reversal is desired.

Mivacron must be stored at 2‑8 °C in a refrigerator, protected from light, and never frozen or shaken. The vial should remain in its original packaging until use, and any unused portion should be discarded according to local regulations after the recommended storage period.

Mivacron is supplied as a sterile powder for reconstitution and is administered intravenously. After reconstitution with the appropriate diluent, the solution is injected as a bolus or infusion under continuous monitoring of neuromuscular function and vital signs.

The most critical risks include anaphylaxis, prolonged neuromuscular blockade leading to extended ventilation, severe hypotension, and life‑threatening cardiac arrhythmias. Prompt recognition and treatment of these events are essential, and facilities should have emergency drugs and equipment readily available.

Mivacron is contraindicated in patients with a known hypersensitivity to mivacurium or any of its excipients. Caution is also advised in individuals with severe hepatic or renal impairment, a history of malignant hyperthermia, or those receiving interacting medications such as aminoglycosides or lithium.